The CHIPS Act was always a bet. The federal government would front billions in grants and equity to domestic chipmakers, and in return, those companies would deliver the manufacturing capacity America needed to stop depending on Taiwan. The implicit assumption was that the money would flow to struggling companies that needed the lifeline.
Nobody modeled for the scenario where the bet starts paying off before the factories are finished.
A $36 Billion Position, Built on a Forecast
Intel's Q1 earnings, reported April 24, were the kind of surprise that rewrites narratives. Demand for Intel CPUs from AI service providers was strong enough that the company sold chips it had originally written off — inventory that had been marked down as unsellable moved out the door. The revenue forecast that followed sent Intel shares to record highs, and the broader chip sector along with them.
The downstream effect on Washington is the part worth tracking. The U.S. government's equity stake in Intel — acquired as part of the CHIPS Act deal structure — has jumped to roughly $36 billion following the share rally, a roughly fourfold increase in value. That's not a rounding error. That's a position large enough to create real political complications around how the government manages its oversight role.
Here's the tension: the CHIPS Act was designed to hold Intel accountable through grant conditions, milestone requirements, and Commerce Department oversight. That accountability structure assumes the government is the creditor and Intel is the supplicant. A $36 billion equity stake flips some of that dynamic. Governments with large profitable positions in companies face pressure — political, institutional, and financial — not to rock the boat. The incentive to demand hard answers about fab construction timelines or process node delays gets softer when the stock is up.
I'm not suggesting Commerce will abandon its oversight role. But the accountability architecture deserves scrutiny now that the financial relationship has changed shape.
What the Earnings Story Doesn't Tell You
The CPU demand surge is real. The AI inference workload driving it is real. What the earnings call doesn't resolve is the question this newsletter has been tracking since the beginning: are Intel's U.S. fabs actually on track to deliver the advanced manufacturing capacity the CHIPS Act was designed to create?
Strong CPU sales in Q1 2026 are largely a product of existing manufacturing capacity — much of it outside the United States. The whole point of the CHIPS Act investment was to build new domestic capacity at advanced nodes. A good quarter for legacy products doesn't move that needle. The milestones that matter are still the ones tied to Intel 18A process readiness, Ohio fab construction completion, and yield rates on advanced nodes — none of which the Q1 earnings summary addresses.
The pattern here is familiar: a strong financial quarter generates positive coverage, the stock rallies, and the harder questions about physical construction progress get buried under the good news cycle. Watch for Intel's next investor presentation or Commerce Department milestone disclosure to see whether the fab timeline has actually held.
China Tightens the Circuit
While Intel's week was good news for Washington's balance sheet, Beijing was moving in a direction that deserves its own thread. China plans to require government approval before leading AI startups and tech firms can accept U.S. capital — a structural move to reduce American visibility into, and influence over, China's domestic technology development.
The semiconductor angle is indirect but real. China's domestic chip ambitions depend on continued investment flows into companies like SMIC and its equipment ecosystem. Restricting U.S. capital doesn't just limit American investors — it limits the information flow that comes with investment relationships, making it harder to track actual capability progress through financial disclosures and investor communications. The opacity that already frustrates export control enforcement gets thicker.
This connects directly to the enforcement backlog problem covered two weeks ago: BIS is already struggling to assess what Chinese chipmakers can actually produce. A formal capital restriction regime makes that assessment harder, not easier.
The Milestone That Actually Matters This Quarter
The forward-looking question isn't whether Intel's stock holds its gains. It's whether the Commerce Department's next CHIPS Act progress report — expected to cover fab construction milestones tied to the initial grant disbursements — reflects the same optimism as the earnings call.
UMC's April 29 earnings added one more data point worth noting: the Taiwanese foundry flagged headwinds but predicted resilient demand and announced price increases. Foundry pricing power is a leading indicator of where capacity actually sits relative to demand. If even second-tier foundries are raising prices, the argument for accelerating U.S. domestic capacity gets stronger — which is exactly the argument the CHIPS Act was built on.
The bet is paying off on paper. The question is whether the concrete is being poured.